Urological Research

, Volume 37, Issue 4, pp 227–229 | Cite as

Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics

  • Gerhard J. Molderings
  • Gerold Solleder
  • Ulrich W. Kolck
  • Jürgen Homann
  • Detlev Schröder
  • Ivar von Kügelgen
  • Roland Vorreuther
Case Report

Abstract

Urolithiasis is expected to cause a considerable complication in patients with systemic mastocytosis. The aim of the present report is to demonstrate that due to pathological activation and irritability of mast cells, special features in the diagnostic investigation and therapy of urolithiasis have to be considered in patients with systemic mastocytosis. The clinical presentation, diagnostic investigation and therapeutic procedure of urolithiasis in a patient with systemic mastocytosis are described. Urolithiasis may be a significant complication of systemic mastocytosis. Non-contrast CT is the main tool for diagnosing urolithiasis after a detailed history and clinical exam. Patients with systemic mastocytosis should receive a premedication composed of a glucocorticoid and H1- and H2-histamine receptor antagonists. An increased vulnerability of mucosal tissues is expected in patients with systemic mastocytosis that may limit the options of operative and postoperative therapy. Opioids should be used cautiously for analgesia in patients with systemic mastocytosis.

Keywords

Urolithiasis Systemic mastocytosis Ureterorenoscopy Analgesia 

References

  1. 1.
    Valent P, Akin C, Escribano L et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435–453. doi:10.1111/j.1365-2362.2007.01807.x PubMedCrossRefGoogle Scholar
  2. 2.
    Ruëff F, Dugas-Breit S, Bauer C et al (2006) Mastocytosis—clinical picture and diagnosis. Dtsch Med Wochenschr 131:1616–1621. doi:10.1055/s-2006-947809 PubMedCrossRefGoogle Scholar
  3. 3.
    Molderings GJ, Kolck UW, Scheurlen C et al (2007) Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 42:1045–1053. doi:10.1080/00365520701245744 PubMedCrossRefGoogle Scholar
  4. 4.
    Alfter K, von Kügelgen I, Haenisch B et al (2008) New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. doi:10.1111/j.1478-3231.2008.01839.x
  5. 5.
    Manion SP, Wheeler JS (1996) Systemic mastocytosis: a possible aetiology of nephrolithiasis. Br J Urol 78:643–644PubMedGoogle Scholar
  6. 6.
    Lanternier F, Cohen-Akenine A, Palmerini F et al (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 3:e1906PubMedCrossRefGoogle Scholar
  7. 7.
    Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32–36. doi:10.1016/j.semarthrit.2006.03.004 PubMedCrossRefGoogle Scholar
  8. 8.
    Caudarella R, Vescini F, Buffa A et al (2004) Osteoporosis and urolithiasis. Urol Int 72(Suppl 1):17–19. doi:10.1159/000076585 PubMedCrossRefGoogle Scholar
  9. 9.
    Díaz-López B, Cannata-Andía JB (2006) Supplementation of vitamin D and calcium: advantages and risks. Nephrol Dial Transpl 21:2375–2377. doi:10.1093/ndt/gfl286 CrossRefGoogle Scholar
  10. 10.
    Carter MC, Uzzaman A, Scott LM et al (2008) Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 107:422–427PubMedCrossRefGoogle Scholar
  11. 11.
    Liccardi G, Lobefalo G, Di Florio E et al (2008) Strategies for the prevention of asthmatic, anaphylactic and anaphylactoid reactions during the administration of anesthetics and/or contrast media. J Investig Allergol Clin Immunol 18:1–11PubMedGoogle Scholar
  12. 12.
    Fujimoto T, Nishiyama T, Hanaoka K (2005) Inhibitory effect of intravenous anesthetics on mast cell function. Anesth Analg 101:1054–1059. doi:10.1213/01.ane.0000166955.97368.80 PubMedCrossRefGoogle Scholar
  13. 13.
    Sierakowski R, Finlayson B, Landes RR et al (1978) The frequency of urolithiasis in hospital discharge diagnoses in the United States. Invest Urol 15:438–441PubMedGoogle Scholar
  14. 14.
    Hiatt RA, Dales LG, Friedman GD et al (1982) Frequency of urolithiasis in a prepaid medical care program. Am J Epidemiol 115:255–265PubMedGoogle Scholar
  15. 15.
    Tamm EP, Silverman PM, Shuman WP (2003) Evaluation of the patient with flank pain and possible ureteral calculus. Radiology 228:319–329. doi:10.1148/radiol.2282011726 PubMedCrossRefGoogle Scholar
  16. 16.
    Morse RM, Resnick MI (1991) Ureteral calculi: natural history and treatment in an era of advanced technology. J Urol 145:263–265PubMedGoogle Scholar
  17. 17.
    Miller OF, Kane CJ (1999) Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol 162:688–690. doi:10.1097/00005392-199909010-00014 PubMedCrossRefGoogle Scholar
  18. 18.
    Li F (2006) Pharmacologically induced histamine release: sorting out hypersensitivity reactions to opioids. Drug Ther Topics 35:13–16Google Scholar
  19. 19.
    Sheen CH, Schleimer RP, Kulka M (2007) Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation. Allergy 62:532–538. doi:10.1111/j.1398-9995.2007.01345.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Gerhard J. Molderings
    • 1
  • Gerold Solleder
    • 2
  • Ulrich W. Kolck
    • 3
  • Jürgen Homann
    • 3
  • Detlev Schröder
    • 4
  • Ivar von Kügelgen
    • 5
  • Roland Vorreuther
    • 2
  1. 1.Institute of Human GeneticsUniversity Hospital of BonnBonnGermany
  2. 2.Department of UrologyEvangelische Kliniken Bonn, WaldkrankenhausBonnGermany
  3. 3.Department for Internal MedicineEvangelische Kliniken Bonn, WaldkrankenhausBonnGermany
  4. 4.Department of SurgeryEvangelische Kliniken Bonn, WaldkrankenhausBonnGermany
  5. 5.Department of Pharmacology and ToxicologyUniversity of BonnBonnGermany

Personalised recommendations